Sahajanand Medical Technologies Ltd
Sahajanand Medical Technologies Ltd is a medical device company specializing in cardiovascular solutions. Established in 2001, the company develops, manufactures and markets technologically advanced products including coronary stents, balloons, transcatheter valves and occluders for vascular and structural heart interventions.
Overview
About the Company
Sahajanand Medical Technologies Limited was incorporated in October 2001 and operates as a medical technology enterprise focused on developing, manufacturing and commercializing advanced medical devices. The company specializes in vascular intervention and structural heart intervention products, with its portfolio encompassing coronary stents, coronary balloons, transcatheter aortic valve implantation devices, occluders, renal stents and peripheral drug-coated balloons. Its prominent product brands include Supraflex Cruz, Cocoon and Hydra. The company maintains three manufacturing facilities—two in India and one in Thailand—supported by research and development centers in both countries. As of June 30, 2026, the company held 119 granted patents globally with 78 additional applications pending. Its products reach 77 countries through direct, hybrid and distributor-based sales models, with established presence across India, Europe and other international markets. The company employs 1,605 full-time staff members alongside consultants and contract workers.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › The IPO is a 100% Offer for Sale (OFS). The company will not receive any proceeds from the issue. All funds raised through this public offering will be paid to the selling shareholders, including Shree Hari Trust, Dhirajkumar Savjibhai Vasoya, Samara Capital Markets Holding Ltd., Kotak Pre-IPO Opportunities Fund, and NHPEA Sparkle Holding BV.
✅ Strengths
- ✓ Extensive global sales and marketing network across 77 countries
- ✓ Strong research and development capabilities with 119 granted patents
- ✓ Diversified and integrated manufacturing facilities in India and Thailand
- ✓ Leadership position in India and key international markets
- ✓ Proven track record in mergers, acquisitions and strategic collaborations
- ✓ Technologically advanced medical devices in high-barrier market segments
- ✓ Experienced leadership team backed by reputed institutional investors
- ✓ Strong portfolio of vascular and structural heart medical devices
- ✓ Dedicated in-house R&D capabilities driving product innovation
⚠️ Risks
- ! High dependency on revenues from the Supraflex Cruz stent product
- ! Stringent domestic and global regulatory compliance requirements
- ! Vulnerability to foreign currency exchange rate fluctuations
- ! Reliance on limited third-party suppliers for key raw materials
- ! Exposure to pricing controls and healthcare reimbursement caps
- ! No proceeds to company as 100% OFS—entire issue benefits selling shareholders only